Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - India

India

In India, the Neoplasm Treatment market is expected to witness significant growth in the coming years.
By 2024, the projected revenue for this market is estimated to reach INR €6.77bn.
Furthermore, it is anticipated that the market will continue to grow at an annual growth rate of 9.15% from 2024 to 2029, resulting in a market volume of INR €10.49bn by 2029.
When compared to the global market, United States is expected to generate the highest revenue in the Neoplasm Treatment market, with an estimated revenue of €83.98bn in 2024.
India's neoplasm treatment market is witnessing a surge in innovative therapies, driven by the country's robust pharmaceutical research and development capabilities.

Key regions: Europe, Canada, Brazil, United States, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.